ReShape Lifesciences Inc. (RSLS)
| Market Cap | 9.06M |
| Revenue (ttm) | 12.82M |
| Net Income (ttm) | -65.27M |
| Shares Out | 18.69M |
| EPS (ttm) | -4.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,560,241 |
| Open | 0.491 |
| Previous Close | 0.450 |
| Day's Range | 0.450 - 0.517 |
| 52-Week Range | 0.443 - 4.040 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | 3.90 (+705.0%) |
| Earnings Date | Aug 8, 2022 |
About RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomac... [Read more...]
Financial Performance
In 2021, RSLS's revenue was $13.60 million, an increase of 20.36% compared to the previous year's $11.30 million. Losses were -$61.93 million, 186.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for RSLS stock is "Buy." The 12-month stock price forecast is 3.9, which is an increase of 704.95% from the latest price.
News
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate ...
Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022 Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatr...
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Boar...
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
SAN CLEMENTE, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it ha...
ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and We...
Solution will Provide Physician-Led Virtual Weight Loss Coaching Solution will Provide Physician-Led Virtual Weight Loss Coaching
ReShape Lifesciences™ Reports First Quarter 2022 Financial Results and Provides Corporate Update
March 2022 Revenues Exceeded January's and February's, Combined, Indicating DTC Campaign and Other Visibility Activities are Driving Significant Demand for Lap-Band® Procedures
ReShape Lifesciences™ Announces Vernon Vincent to be Recognized as the Distinguished Industry Partner at the ASMBS 20...
SAN CLEMENTE, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Vernon “V...
ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate ...
Webcast to be Held at 8:30 am ET on Monday, May 23, 2022 Webcast to be Held at 8:30 am ET on Monday, May 23, 2022
ReShape Lifesciences to Present at the Q2 Investor Summit
Management will also Present to Members of the Philadelphia Securities Association Management will also Present to Members of the Philadelphia Securities Association
ReShape Lifesciences™ Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update
Conference Call to be Held at 5:30 pm ET Today Conference Call to be Held at 5:30 pm ET Today
ReShape Lifesciences™ Experiences Continued Momentum of Direct-to-Consumer Marketing Campaign for the Lap-Band®
New Generation of Patients are Engaged as E videnced by Surge in Website Traffic and Doctor Referrals
ReShape Lifesciences™ to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
Full Year Revenue Increased by Approximately 20%, from $11.3 M to $13.6 M
ReShape Lifesciences™ to Participate in the American Society for Metabolic and Bariatric Surgery's (ASMBS) Leadership...
Company to Present and Exhibit its Next-Generation Lap-Band® Program Including its Supportive r e s hape c are ™ Virtual Health Coaching Platform
ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Com...
Seasoned Executive Brings Significant Operational and Commercial Experience to Accelerate the Company's Growth Seasoned Executive Brings Significant Operational and Commercial Experience to Accelerate t...
ReShape Lifesciences to Webcast Live at Life Sciences Investor Forum on December 16th
SAN CLEMENTE, Calif., Dec. 9, 2021 /PRNewswire/ -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that Bart Bandy...
ReShape Lifesciences Witnesses Great Success with Direct-to-Consumer Marketing Campaign
National advertising campaign and Virtual Media Tour achieve all key performance indicators National advertising campaign and Virtual Media Tour achieve all key performance indicators
ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results
Webinar to follow at 8:45 a.m. ET today Webinar to follow at 8:45 a.m. ET today
ReShape Lifesciences to Report Third Quarter 2021 Financial and Operational Results on Thursday, November 11, 2021
SAN CLEMENTE, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced today that it wil...
ReShape Lifesciences to Present at Dawson James 6th Annual Small Cap Growth Conference
SAN CLEMENTE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced Thomas Stankovich...
ReShape Lifesciences™ Featured in BioTuesdays
SAN CLEMENTE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced the company was highlighted in ...
7 Reddit Penny Stocks Dazzling Investors with Low Floats
Penny stocks are incredibly risky. But if you must engage this sector, you certainly have a better chance with low-float securities.
ReShape Lifesciences™ to Present at Oppenheimer Fall Healthcare Life Sciences and Med Tech Summit on September 20, 2021
SAN CLEMENTE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced that its leader...
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
ReShape Lifesciences™ Appoints Al Diaz as Vice President of Operations and Research and Development
SAN CLEMENTE, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss solutions company, today announced the appointment of Al Diaz as Vi...
ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update
Webinar to follow at 8:30 a.m. today SAN CLEMENTE, CA / ACCESSWIRE / August 16, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a leading developer and distributor of minimally invasive medical devices ...